Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute iloprost inhalation in exercise-induced pulmonary hypertension after COVID-19
2022-003725-22Phase 2Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iloprost in pulmonary hypertension (PH), sponsored by Justus Liebig University Giessen. Primary endpoints: Tolerability of inhaled iloprost, Change in pulmonary vascular resistance during exercise and 2 more. Started Jan 2023; status: completed.
02
Drugs
iloprost
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2022-003725-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003725-22.